EP3252074A4 - Anticorps anti-alk2 - Google Patents

Anticorps anti-alk2 Download PDF

Info

Publication number
EP3252074A4
EP3252074A4 EP16743511.4A EP16743511A EP3252074A4 EP 3252074 A4 EP3252074 A4 EP 3252074A4 EP 16743511 A EP16743511 A EP 16743511A EP 3252074 A4 EP3252074 A4 EP 3252074A4
Authority
EP
European Patent Office
Prior art keywords
alk2 antibody
alk2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16743511.4A
Other languages
German (de)
English (en)
Other versions
EP3252074A1 (fr
Inventor
Takenobu Katagiri
Kenji Osawa
Sho Tsukamoto
Shinnosuke Tsuji
Yoshirou KAWAGUCHI
Kensuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Saitama Medical University
Original Assignee
Daiichi Sankyo Co Ltd
Saitama Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Saitama Medical University filed Critical Daiichi Sankyo Co Ltd
Publication of EP3252074A1 publication Critical patent/EP3252074A1/fr
Publication of EP3252074A4 publication Critical patent/EP3252074A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP16743511.4A 2015-01-30 2016-01-29 Anticorps anti-alk2 Pending EP3252074A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015017882 2015-01-30
PCT/JP2016/052602 WO2016121908A1 (fr) 2015-01-30 2016-01-29 Anticorps anti-alk2

Publications (2)

Publication Number Publication Date
EP3252074A1 EP3252074A1 (fr) 2017-12-06
EP3252074A4 true EP3252074A4 (fr) 2018-07-11

Family

ID=56543512

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16743511.4A Pending EP3252074A4 (fr) 2015-01-30 2016-01-29 Anticorps anti-alk2

Country Status (9)

Country Link
US (3) US10428148B2 (fr)
EP (1) EP3252074A4 (fr)
JP (2) JP6763783B2 (fr)
KR (1) KR20170105558A (fr)
CN (2) CN113980131A (fr)
BR (1) BR112017015661A2 (fr)
CA (1) CA2975376A1 (fr)
TW (2) TWI774028B (fr)
WO (1) WO2016121908A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170105558A (ko) * 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
AU2017348743C1 (en) * 2016-10-31 2022-03-03 National University Corporation Tottori University Human antibody–producing non-human animal and method for preparing human antibodies using same
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3564232B1 (fr) 2016-12-27 2022-01-26 Riken Composé inhibiteur de signal bmp
JP7125979B2 (ja) * 2018-03-05 2022-08-25 学校法人 埼玉医科大学 異所性骨化の治療又は予防のための医薬組成物
CN109438572A (zh) * 2018-10-15 2019-03-08 上海药明生物技术有限公司 连续应用亲和层析和陶瓷羟基磷灰石层析分离抗体药物的方法
WO2020086730A1 (fr) * 2018-10-23 2020-04-30 Keros Therapeutics, Inc. Anticorps alk2 et procédés d'utilisation associés
WO2020118011A1 (fr) * 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anticorps anti-alk2 et leurs utilisations
JP2021017416A (ja) * 2019-07-19 2021-02-15 国立大学法人京都大学 Ａｌｋ２の変異を有する疾患の治療または予防用医薬組成物
US20220267453A1 (en) * 2019-07-26 2022-08-25 Saitama Medical University Antibody recognizing extracellular region of alk2/acvr1
CA3167441A1 (fr) 2020-02-11 2021-08-19 Vincent J. Idone Anticorps anti-acvr1 et leurs utilisations
CN115515632A (zh) * 2020-02-28 2022-12-23 布里格姆妇女医院 通过多特异性抗体选择性调节转化生长因子β超家族信号传导
EP4047955A1 (fr) 2021-02-17 2022-08-24 Oticon A/s Prothèse auditive comprenant un système de commande de rétroaction
US20240150474A1 (en) 2022-10-27 2024-05-09 Regeneron Pharmaceuticals, Inc. Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014051109A1 (fr) * 2012-09-28 2014-04-03 協和発酵キリン株式会社 Anticorps anti-bmp9 humain et agent thérapeutique pour une maladie d'ossification ectopique contenant ledit anticorps comme principe actif

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895711B2 (en) * 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2332995A1 (fr) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
US20130078718A1 (en) * 2010-03-09 2013-03-28 President And Fellows Of Harvard College Conversion of vascular endothelial cells into multipotent stem-like cells
US9334331B2 (en) * 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014078306A1 (fr) * 2012-11-13 2014-05-22 Regeneron Pharmaceuticals, Inc. Anticorps anti-récepteur de prokinéticine (prokr) et leurs utilisations
KR20170105558A (ko) * 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
CN107488625B (zh) 2017-08-31 2018-12-21 广州蕊特生物科技有限公司 一种胎牛血清替代物及其制备方法和应用
JP7125979B2 (ja) 2018-03-05 2022-08-25 学校法人 埼玉医科大学 異所性骨化の治療又は予防のための医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014051109A1 (fr) * 2012-09-28 2014-04-03 協和発酵キリン株式会社 Anticorps anti-bmp9 humain et agent thérapeutique pour une maladie d'ossification ectopique contenant ledit anticorps comme principe actif

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FREDERICK S KAPLAN ET AL: "From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva", EXPERT OPINION ON ORPHAN DRUGS, vol. 1, no. 8, 1 August 2013 (2013-08-01), pages 637 - 649, XP055228116, DOI: 10.1517/21678707.2013.825208 *
JULIANO C DA SILVEIRA ET AL: "Regulation of ACVR1 and ID2 by cell-secreted exosomes during follicle maturation in the mare", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, BIOMED CENTRAL LTD, GB, vol. 12, no. 1, 26 May 2014 (2014-05-26), pages 44, XP021188085, ISSN: 1477-7827, DOI: 10.1186/1477-7827-12-44 *
N.N.: "ACTR-I (N-a5): sc-5671", SANTA CRUZ ONLINE CATALOGUE, 1 January 2014 (2014-01-01), pages 1 - 1, XP055478378, Retrieved from the Internet <URL:http://datasheets.scbt.com/sc-5671.pdf> [retrieved on 20180525] *
N.N.: "sc-374523", SANT CRUZ ONLINE CATALOGUE, 1 January 2014 (2014-01-01), XP055478395, Retrieved from the Internet <URL:https://datasheets.scbt.com/sc-374523.pdf> [retrieved on 20180525] *
See also references of WO2016121908A1 *
TAKENOBU KATAGIRI: "Heterotopic Bone Formation Induced by Bone Morphogenetic Protein Signaling:Fibrodysplasia Ossificans Progressiva", J. ORAL BIOSCI, vol. 52, no. 1, 1 January 2010 (2010-01-01), pages 33 - 41, XP055472094 *

Also Published As

Publication number Publication date
TWI774028B (zh) 2022-08-11
CN107207604A (zh) 2017-09-26
BR112017015661A2 (pt) 2018-03-20
JP6763783B2 (ja) 2020-09-30
US10428148B2 (en) 2019-10-01
CN113980131A (zh) 2022-01-28
KR20170105558A (ko) 2017-09-19
CA2975376A1 (fr) 2016-08-04
JP2021006535A (ja) 2021-01-21
TW201636368A (zh) 2016-10-16
US20220041738A1 (en) 2022-02-10
JPWO2016121908A1 (ja) 2017-11-09
US20200002427A1 (en) 2020-01-02
TW202110894A (zh) 2021-03-16
JP7101732B2 (ja) 2022-07-15
US11447554B2 (en) 2022-09-20
EP3252074A1 (fr) 2017-12-06
US11312776B2 (en) 2022-04-26
WO2016121908A1 (fr) 2016-08-04
US20180118835A1 (en) 2018-05-03
CN107207604B (zh) 2021-10-26
TWI703156B (zh) 2020-09-01

Similar Documents

Publication Publication Date Title
EP3498840A4 (fr) Anticorps anti-lag-3
EP3481869A4 (fr) Anticorps anti-cd73
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
EP3354729A4 (fr) Anticorps antagoniste de prédominance de répétitions de glycoprotéine-a (garp)
EP3212231A4 (fr) Anticorps anti-tim -3
EP3569709A4 (fr) Anticorps anti-gpc3
EP3212229A4 (fr) Anticorps anti-tim -3
EP3242894A4 (fr) Anticorps anti-pd-l1
EP3252074A4 (fr) Anticorps anti-alk2
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3349794A4 (fr) Anticorps anti-cd115
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3381941A4 (fr) Anticorps anti-epha4
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3177650A4 (fr) Anticorps anti-céramide
EP3266872A4 (fr) Nouveaux anticorps anti-pad4
EP3336185A4 (fr) Anticorps
EP3129476A4 (fr) Anticorps anti-nme
EP3178931A4 (fr) Anticorps anti-orai1
EP3112463A4 (fr) Nouvel anticorps anti-présepsine
EP3336184A4 (fr) Anticorps
EP3330376A4 (fr) ANTICORPS ANTI-PROTÉINE Eva1
EP3262070A4 (fr) Anticorps anti-amyloïde-bêta
EP3078674A4 (fr) Anticorps anti-vegf

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240944

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20180612

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/10 20060101ALI20180604BHEP

Ipc: C07K 16/28 20060101AFI20180604BHEP

Ipc: C12N 15/09 20060101ALI20180604BHEP

Ipc: C12N 1/19 20060101ALI20180604BHEP

Ipc: A61K 45/00 20060101ALI20180604BHEP

Ipc: C12N 1/15 20060101ALI20180604BHEP

Ipc: A61P 19/08 20060101ALI20180604BHEP

Ipc: C12P 21/08 20060101ALI20180604BHEP

Ipc: C12N 1/21 20060101ALI20180604BHEP

Ipc: A61K 39/395 20060101ALI20180604BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231026